LY-2275796

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameLY-2275796
Drug Alias NameLY2275796 sodiumISIS-EIF4ERxLY-2275796eIF-4E ASOISIS-183750 +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionEukaryotic translation initiation factor 4E inhibitors
TargetsEukaryotic translation initiation factor 4E
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandRomania +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIonis Pharmaceuticals IncNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A